Heather Angel Syrett
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Heather Angel Syrett has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Andrew D. Ellington
University of Texas at Austin
2 shared publications - James R. Collett
Pacific Northwest National Laboratory
1 shared publication - Kristin M Thompson
Department of Chemistry and Biochemistry, Institute for Cellular and Molecular Biology, University of Texas at Austin, Austin, TX 78712, USA
1 shared publication - Scott M. Knudsen
Department of Chemistry, New York University, New York, New York 10003, and Department of Chemistry & Biochemistry, University of Texas, Austin, Texas 78712
1 shared publication
Latest Publications
- 1 January 2009
- Published by Springer Nature
- p. 287-308
Aptamer Microarrays
- Open Access
- 4 December 2002
- Published by Springer Nature in BMC Biotechnology
- Vol. 2 (1) , 21
Group I aptazymes as genetic regulatory switches
Allosteric ribozymes (aptazymes) that have extraordinary activation parameters have been generated in vitro by design and selection. For example, hammerhead and ligase ribozymes that are activated by small organic effectors and protein effectors have been selected from random sequence pools appended to extant ribozymes. Many ribozymes, especially self-splicing introns, are known control gene regulation or viral replication in vivo. We attempted to generate Group I self-splicing introns that were activated by a small organic effector, theophylline, and to show that such Group I aptazymes could mediate theophylline-dependent splicing in vivo. By appending aptamers to the Group I self-splicing intron, we have generated a Group I aptazyme whose in vivo splicing is controlled by exogenously added small molecules. Substantial differences in gene regulation could be observed with compounds that differed by as little as a single methyl group. The effector-specificity of the Group I aptazyme could be rationally engineered for new effector molecules. Group I aptazymes may find applications as genetic regulatory switches for generating conditional knockouts at the level of mRNA or for developing economically viable gene therapies.
- 4 December 2002
- Published by Springer Nature in BMC Biotechnology
- Vol. 2 (1) , 21
Open AccessGroup I aptazymes as genetic regulatory switches
Allosteric ribozymes (aptazymes) that have extraordinary activation parameters have been generated in vitro by design and selection. For example, hammerhead and ligase ribozymes that are activated by small organic effectors and protein effectors have been selected from random sequence pools appended to extant ribozymes. Many ribozymes, especially self-splicing introns, are known control gene regulation or viral replication in vivo. We attempted to generate Group I self-splicing introns that were activated by a small organic effector, theophylline, and to show that such Group I aptazymes could mediate theophylline-dependent splicing in vivo. By appending aptamers to the Group I self-splicing intron, we have generated a Group I aptazyme whose in vivo splicing is controlled by exogenously added small molecules. Substantial differences in gene regulation could be observed with compounds that differed by as little as a single methyl group. The effector-specificity of the Group I aptazyme could be rationally engineered for new effector molecules. Group I aptazymes may find applications as genetic regulatory switches for generating conditional knockouts at the level of mRNA or for developing economically viable gene therapies.